Bionano Genomics Croissance future
Future contrôle des critères 2/6
Bionano Genomics devrait augmenter ses bénéfices et ses revenus de 39.7% et de 21.3% par an respectivement, tandis que le BPA devrait croître de croître de 61.4% par an.
Informations clés
39.7%
Taux de croissance des bénéfices
61.43%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 17.5% |
| Taux de croissance des recettes | 21.3% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 13 Apr 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).Mise à jour du récit • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).
Mise à jour du récit • Apr 05
BNGO: Future Gene Editing Quality Control Breakthroughs Will Drive Upside Potential
Analysts have cut their price target on Bionano Genomics roughly in half, to around $4.00 from about $8.00, pointing to a higher discount rate, slightly softer revenue growth expectations near 26%, a modestly better profit margin near 16%, and a higher future P/E multiple closer to 8x as key drivers of the reset. What's in the News A multicenter study in the American Journal of Hematology reported that Bionano's optical genome mapping, or OGM, was concordant with traditional methods in multiple myeloma and identified pathogenic or likely pathogenic abnormalities in a large cohort of 211 samples, including cases where standard tests such as karyotyping and FISH did not yield results (American Journal of Hematology).
Mise à jour du récit • Mar 22
BNGO: Gene Editing Safety Data Will Support Future Upside Potential
Analysts have adjusted their price target for Bionano Genomics slightly, reflecting updated assumptions around discount rate, profit margin, revenue growth and future P/E. Together, these factors point to a modest recalibration of their valuation outlook in dollar terms.Mise à jour du récit • Mar 07
BNGO: Gene Editing Safety Insights Will Support Long-Term Upside Potential
Analysts have lowered their price target on Bionano Genomics by $2.00 to $5.50, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively point to a more conservative outlook for the shares.Mise à jour du récit • Feb 20
BNGO: Gene Editing Study And Mapping Sensitivity Will Support Future Upside
Analysts have raised their price target for Bionano Genomics to $12.59 from $12.37, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect a recalibrated risk and earnings profile. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used optical genome mapping, or OGM, to assess genomic alterations from multiple gene editing approaches, including transposons, lentiviral transduction, and CRISPR-Cas9 locus insertion (Key Developments).Mise à jour du récit • Feb 06
BNGO: Gene Editing QC Study Will Support Long-Term Upside
Analysts have trimmed their price targets for Bionano Genomics, citing slightly higher assumed discount rates and modest tweaks to long term revenue growth, profit margin and future P/E assumptions that leave their fair value estimate broadly unchanged at around $8.00. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used its optical genome mapping (OGM) technology to detect genomic alterations introduced by transposons, lentiviral transduction and CRISPR-Cas9 locus insertion in human iPSC lines, supporting OGM as a potential tool for genome integrity QC in gene editing workflows (Key Developments).Article d’analyse • Jan 30
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues
With a price-to-sales (or "P/S") ratio of 0.5x Bionano Genomics, Inc. ( NASDAQ:BNGO ) may be sending very bullish...Mise à jour du récit • Jan 23
BNGO: Clinical Study And Genome Mapping Progress Will Support Future Upside
Analysts have adjusted their price target on Bionano Genomics slightly, reflecting modest tweaks to assumptions on discount rate, profit margin, and future P/E. These changes keep their fair value estimate broadly unchanged at about $7.50 per share.Mise à jour du récit • Jan 09
BNGO: Leukemia Study And 2025 Revenue Outlook Will Support Long-Term Upside
Analysts have slightly adjusted their price target for Bionano Genomics, citing modest tweaks in assumptions around discount rate, revenue growth, profit margin, and future P/E as the drivers of this update. What's in the News Bionano Genomics issued earnings guidance for the fourth quarter of 2025, with revenue projected in a range of US$7.5 million to US$7.9 million.Mise à jour du récit • Dec 23
BNGO: Study-Driven Revenue Outlook Will Support Stronger Long-Term Upside Potential
Analysts have lowered their fair value estimate for Bionano Genomics from 11.00 dollars to 8.00 dollars. This reflects a higher perceived risk and cost of capital, despite slightly stronger expectations for revenue growth, profitability, and future valuation multiples.Mise à jour du récit • Dec 09
BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025
Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).Mise à jour du récit • Nov 25
BNGO: Clinical Study Results Will Drive Increased Demand Through 2025
Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).Article d’analyse • Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders would be excited to see that the share price has had a great month...Mise à jour du récit • Aug 15
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.Article d’analyse • Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy...
Nouveau récit • Apr 16
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Article d’analyse • Apr 05
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
To the annoyance of some shareholders, Bionano Genomics, Inc. ( NASDAQ:BNGO ) shares are down a considerable 26% in the...Article d’analyse • Feb 11
Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders that were waiting for something to happen have been dealt a blow...Article d’analyse • Dec 17
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Article d’analyse • Aug 29
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 54 | -17 | N/A | N/A | 1 |
| 12/31/2027 | 43 | -23 | N/A | N/A | 1 |
| 12/31/2026 | 32 | -31 | N/A | N/A | 2 |
| 3/31/2026 | 29 | -32 | -19 | -19 | N/A |
| 12/31/2025 | 29 | -26 | -16 | -16 | N/A |
| 9/30/2025 | 29 | -39 | -19 | -19 | N/A |
| 6/30/2025 | 27 | -74 | -26 | -26 | N/A |
| 3/31/2025 | 28 | -84 | -44 | -44 | N/A |
| 12/31/2024 | 31 | -112 | -69 | -69 | N/A |
| 9/30/2024 | 33 | -136 | -93 | -92 | N/A |
| 6/30/2024 | 37 | -204 | -106 | -105 | N/A |
| 3/31/2024 | 37 | -227 | -122 | -121 | N/A |
| 12/31/2023 | 36 | -232 | -127 | -125 | N/A |
| 9/30/2023 | 34 | -227 | -132 | -130 | N/A |
| 6/30/2023 | 32 | -147 | -136 | -133 | N/A |
| 3/31/2023 | 30 | -140 | -127 | -125 | N/A |
| 12/31/2022 | 28 | -133 | -128 | -125 | N/A |
| 9/30/2022 | 26 | -117 | -119 | -116 | N/A |
| 6/30/2022 | 23 | -106 | -109 | -106 | N/A |
| 3/31/2022 | 21 | -92 | -93 | -91 | N/A |
| 12/31/2021 | 18 | -72 | -73 | -72 | N/A |
| 9/30/2021 | 16 | -61 | -59 | -58 | N/A |
| 6/30/2021 | 13 | -51 | -49 | -49 | N/A |
| 3/31/2021 | 11 | -41 | -44 | -44 | N/A |
| 12/31/2020 | 9 | -41 | -38 | -38 | N/A |
| 9/30/2020 | 7 | -37 | -36 | -36 | N/A |
| 6/30/2020 | 8 | -33 | -32 | -32 | N/A |
| 3/31/2020 | 9 | -32 | -31 | -31 | N/A |
| 12/31/2019 | 10 | -30 | N/A | -30 | N/A |
| 9/30/2019 | 11 | -28 | N/A | -24 | N/A |
| 6/30/2019 | 11 | -27 | N/A | -23 | N/A |
| 3/31/2019 | 12 | -23 | N/A | -20 | N/A |
| 12/31/2018 | 12 | -18 | N/A | -20 | N/A |
| 9/30/2018 | 11 | -18 | N/A | -19 | N/A |
| 6/30/2018 | 11 | -18 | N/A | -18 | N/A |
| 3/31/2018 | 10 | -22 | N/A | -20 | N/A |
| 12/31/2017 | 10 | -23 | N/A | -21 | N/A |
| 12/31/2016 | 7 | -19 | N/A | -23 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: BNGO devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: BNGO devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: BNGO devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de BNGO ( 21.3% par an) devrait croître plus rapidement que le marché US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de BNGO ( 21.3% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de BNGO devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 19:44 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bionano Genomics, Inc. est couverte par 5 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |